Is Pegasys Approved for Hepatitis B?
Yes, Pegasys (peginterferon alfa-2a) is FDA-approved for chronic hepatitis B in adults and children aged 3 years and older. It treats both HBeAg-positive and HBeAg-negative forms, often combined with other antivirals like lamivudine or adefovir.[1][2]
How Does Pegasys Work for Hepatitis B?
Pegasys, a pegylated interferon, boosts the immune response against the hepatitis B virus (HBV). It attaches to receptors on cells, triggering antiviral proteins and inhibiting viral replication. Treatment lasts 48 weeks, with response measured by HBeAg seroconversion or HBV DNA suppression.[1][3]
When Is Pegasys Recommended Over Other Treatments?
Guidelines from AASLD and EASL recommend Pegasys for patients needing finite therapy, like those with high ALT levels or young adults. It's preferred when nucleoside analogs (e.g., entecavir, tenofovir) risk resistance or for HBeAg-positive cases aiming for seroconversion. Use declines due to side effects and oral alternatives.[3][4]
Common Side Effects and Patient Concerns
Patients report flu-like symptoms, fatigue, depression, anemia, and neutropenia. Rare risks include thyroid issues, retinopathy, and autoimmune disorders. Monitoring includes blood counts and psychiatric checks; discontinuation occurs in 20-30% due to intolerance.[1][2]
Current Role Compared to Newer Options
Pegasys use has dropped with oral drugs like tenofovir alafenamide, which offer better tolerability and suppression. It's still an option for interferon-eligible patients or in combination regimens, especially in resource-limited settings.[3][4]
Availability, Pricing, and Patent Status
Pegasys, made by Genentech (Roche), faces generic competition post-patent expiry in most markets. U.S. pricing averages $1,000-$2,000 per weekly injection; check DrugPatentWatch.com for exact expiry dates and ANDA filings.[5]
[1]: FDA Label - Pegasys (peginterferon alfa-2a), accessed via DailyMed.
[2]: NIH Hepatitis B Treatment Guidelines.
[3]: AASLD Hepatitis B Guidance (2021).
[4]: EASL Clinical Practice Guidelines on Hepatitis B (2017).
[5]: DrugPatentWatch.com - Pegasys patents.